Parexel has formed an alliance with a leading Taiwanese hospital to provide drug development services in the country.
The deal with the National Taiwan University Hospital (NTUH) continues the contract research organisation’s (CRO) expansion in Asia as it seeks to position itself to work more with both local and global biopharmaceutical companies.
Joe Avellone, corporate senior vice president of clinical research services at Parexel, said: “Partnering with National Taiwan University Hospital further enhances our ability to meet the increasing demand from our clients to provide a full scope of phase I-IV clinical trials in a rapidly growing market.
“The National Taiwan University Hospital is well-known and highly respected in Taiwan. We are pleased to have the opportunity to work together to advance our biopharmaceutical clients’ programmes in the region and help them to compete more effectively in the global marketplace.”
The CRO said its latest collaboration would “drive greater efficiency” for trial sponsors and help the partners create innovative development and marketing solutions for the region.
Ming–Fong Chen, superintendent at NTUH, said: “This partnership will bring opportunities for both Parexel and NTUH to leverage our combined expertise in order to accelerate clinical development programmes in Taiwan and meet patients’ need for more effective treatments.”
The deal follows two agreements in nearby South Korea. In February, Parexel joined up with Seoul’s ASAN Medical Center (AMC) to expand the clinical trial services it offers throughout Asia.
Then in July, the CRO was subsequently chosen by government consortium the Korea Drug Development Fund (KDDF) to help Korean companies develop and commercialise healthcare products for the global market.